Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio’s proprietary LuxSit de novo luciferase technology and NovoBodies. The partnership allows SignalChem Biotech to incorporate these AI-designed proteins into custom luminescent assay development and protein-fusion services for third-party customers, marking a significant step in expanding Sino Biological’s specialized contract research organization (CRO) capabilities.
The agreement aligns with Sino Biological’s broader strategy of integrating AI-enabled technologies across its global life science tools and services portfolio. By leveraging Monod Bio’s innovative protein designs, SignalChem Biotech can offer researchers more efficient pathways to high-quality discovery candidates. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized the importance of this collaboration, stating, "By incorporating Monod Bio’s AI-designed protein technologies into SignalChem’s custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."
Monod Bio’s LuxSit luciferase is an AI-designed enzyme engineered for use in robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows, enabling researchers to detect and quantify biological interactions with greater precision and speed.
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, expressed optimism about the partnership: "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
The licensing agreement is non-exclusive, allowing Monod Bio to continue partnering with other companies. It also supports Sino Biological’s goal of enhancing its CRO services, which are critical for drug discovery and life science research. SignalChem Biotech, with its specialized reagents and CRO services, is well-positioned to leverage these technologies to serve a wide range of customers across Asia, North America, and Europe.
This collaboration underscores the growing importance of AI in protein design and its application in commercial research tools. By combining Monod Bio’s cutting-edge AI-designed proteins with SignalChem’s assay development expertise, the partnership aims to accelerate research programs and improve the efficiency of drug discovery processes. The integration of these technologies into SignalChem’s platform could lead to the development of more sensitive and specific assays, benefiting researchers in academia and industry alike.
As the life science industry continues to evolve, partnerships like this highlight the value of AI-driven innovations in addressing complex biological questions. The agreement between Monod Bio and SignalChem Biotech represents a strategic move to bring advanced protein engineering tools to a wider audience, potentially transforming how custom assays are developed and utilized in research settings.
